Vulnerability · CVE-2026-109652
Frappe ERPNext before 15.119.1 and 16.x before 16.32.0 contains a server-side template injection vulnerability because user-controlled message fields are not validated…
Published Oct 12, 2026 · catalog updated Oct 14, 2026 · the affected product
Check if you run it
No confirmed exploitation is on record for CVE-2026-109652. EPSS is 0.30%. Act only if a listed version of the affected product is installed.
Gaps on this record
- No plain product name is stored. The page cannot tell you which product to check.
- No version range is stored. A customer cannot check an installed version against this record.
- No vendor fix or required action is stored. Compare the linked advisory before you change production.
- Severity
- High8.7
- Known exploitation
- Not in CISA/VulnCheck KEV
- EPSS
- 0.30%
- Remediation
- Advisory link
- Affected products
- See sources for product scope
Frappe ERPNext before 15.119.1 and 16.x before 16.32.0 contains a server-side template injection vulnerability because user-controlled message fields are not validated before template rendering, allowing expressions to run in an unrestricted context. Authenticated attackers holding a common operational role can inject template expressions to read and write arbitrary database data, delete documents, send outbound requests from the server, and send mail from the site.
No affected version ranges are stored yet. Use the vendor advisory before you decide this record does not apply.
How to fix CVE-2026-109652
Recommended remediation
A patch or advisory reference is linked. Open the original publisher for availability by product version.
Official advisories
What to do
Three questions, each answered from this record only. Confirm the vendor advisory before you patch.
Should you patch?
No confirmed exploitation is on record for CVE-2026-109652. EPSS is 0.30%. Act only if a listed version of the affected product is installed.
Which versions are affected?
Affected version ranges are not on this record. Compare the installed version with the linked vendor advisory before you change production.
What should an analyst verify?
CWE-1336: Improper Neutralization of Special Elements Used in a Template Engine. EPSS 0.30%. There is no CISA KEV listing. No Exploit-DB or Metasploit reference is linked. Use the source links for the original advisory.
Code
The project this record applies to. Exploit listings stay in References.
Timeline
Detection, updates, and resolution for this record.
Oct 12, 2026 · NIST NVD
Detected
Frappe ERPNext before 15.119.1 and 16.x before 16.32.0 contains a server-side template injection vulnerability because user-controlled message fields are not validated before template rendering, allowing expressions to run in an unrestricted context. Authenticated attackers holding a common operational role can inject template expressions to read and write arbitrary database data, delete documents
Oct 14, 2026 · NIST NVD
Updated
Frappe ERPNext before 15.119.1 and 16.x before 16.32.0 contains a server-side template injection vulnerability because user-controlled message fields are not validated before template rendering, allowing expressions to run in an unrestricted context. Authenticated attackers holding a common operational role can inject template expressions to read and write arbitrary database data, delete documents
Sources
- CVE.orgVulnerability recordCVE-2026-109652
Official CVE identifier
cve.org - FIRST EPSSExploitation probabilityCVE-2026-109652
30-day exploitation probability 0.3%
first.org - NIST NVDVulnerability recordCVE-2026-109652
Frappe ERPNext before 15.119.1 and 16.x before 16.32.0 contains a server-side template injection vulnerability because user-controlled message fields are not validated before template rendering, allowing expressions to run in an unrestricted context. Authenticated attackers holdi
nvd.nist.gov
References
Freshness
Last verified in this catalog Oct 18, 2026. Significant claims (KEV, EPSS, CVSS, affected ranges) come from the source rows above — open the original publisher for the authoritative advisory.